Blood Pressure Monitoring Devices Market: as the WHO's second Global Hypertension Report confirms that only one in five hypertensive adults worldwide has their condition controlled, every clearance that adds a new cardiac indication to an existing monitor now converts a single-purpose cuff into a broader cardiovascular screening tool, so device value is shifting from measurement accuracy alone toward the breadth of conditions one device can detect, and competitive advantage is moving toward platforms that can add clinical claims fastest.

The global blood pressure monitoring devices market size was USD 7.60 Billion in 2025 and is expected to register a revenue CAGR of 7.2% during the forecast period. Market revenue growth is driven by factors such as the global scale of uncontrolled hypertension, the integration of AI-powered cardiac detection into standard BP monitors, and guideline bodies expanding home monitoring recommendations. The first driving factor is the sheer scale of uncontrolled hypertension worldwide. The WHO's second Global Hypertension Report, published in September 2025, documented that approximately 1.4 billion adults had hypertension in 2024, with only about one in five having their condition controlled. The second driving factor is the integration of AI-powered arrhythmia detection into standard home and clinical blood pressure monitors. The third driving factor is guideline bodies formally recommending home blood pressure monitoring for all diagnosed hypertensive patients. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single cleared monitoring platform accumulates additional cardiac indications on the same installed hardware base, which converts one device sale into multiple recurring clinical-value events over its service life. Once a blood pressure monitor earns its baseline clearance, each additional cleared indication, such as atrial fibrillation detection or hypertension screening, adds clinical value to a device a patient or provider already owns, so the platform's value per unit compounds as its indication set widens around the same cuff and sensor hardware. As a result, demand and revenue share are concentrating around platforms that combine blood pressure measurement with additional cleared cardiac indications, and the forecast tilts toward multi-indication monitors rather than single-purpose BP devices. For instance, in November 2024, the FDA granted De Novo authorization to Omron Healthcare's blood pressure monitors with AI-powered atrial fibrillation detection, one of a widening set of cardiac indications now available on hardware originally built to measure blood pressure alone. These are some of the key factors driving revenue growth of the market.

Because home blood pressure monitoring devices are frequently an out-of-pocket purchase in markets without device-specific reimbursement policies, patients in lower-income healthcare systems continue to rely exclusively on office-based measurement despite guideline bodies increasingly recommending home monitoring.

Cuffless accuracy validation is a second constraint, because photoplethysmography-based cuffless devices have not yet consistently demonstrated the same clinical-grade accuracy as cuff-based oscillometric systems, which confines most cuffless devices to a wellness rather than diagnostic-grade regulatory category.

Device literacy and technique variability is a third constraint, since accurate home blood pressure measurement depends on correct cuff sizing, positioning, and measurement technique, and inconsistent patient technique can produce misleading readings even with an accurately calibrated device.

These factors substantially limit blood pressure monitoring devices market growth over the forecast period.

The clearest driver of demand is the scale of uncontrolled hypertension documented in the WHO's most authoritative recent survey of the condition. Blood pressure control depends on patients and providers having reliable, frequent measurement data to guide treatment adjustment, so a population with widespread uncontrolled hypertension is by definition a population that is not being measured or treated frequently enough, creating direct policy pressure to expand monitoring device access. The WHO's second Global Hypertension Report, published in September 2025, documented that approximately 1.4 billion adults had hypertension in 2024, with only about one in five having their blood pressure adequately controlled. In January 2025, the American Heart Association updated its hypertension guidelines to emphasize earlier treatment specifically to reduce dementia and cardiovascular risk, and in January 2026, the European Society of Hypertension issued a consensus statement recommending home blood pressure monitoring for all diagnosed patients. The effect on the market is that device procurement is increasingly written into clinical guidelines as a default rather than an optional add-on to hypertension management. These are some of the key factors driving revenue growth of the market.

The second driver is the integration of AI-powered arrhythmia detection into blood pressure monitors that were originally built to measure blood pressure alone. A blood pressure cuff already captures a pulse waveform during measurement, so an AI algorithm trained to detect arrhythmia patterns in that same waveform can add a new clinical indication to existing hardware through a software and regulatory update rather than a new sensor design. In November 2024, the FDA granted De Novo authorization to Omron Healthcare's IntelliSense AFib algorithm, integrated into blood pressure monitors with AI-powered atrial fibrillation detection. In September 2025, Apple received FDA clearance for a Hypertension Notification Feature that similarly repurposes existing optical sensor data to flag a second cardiovascular condition without new hardware. The effect on the market is that a single device sale increasingly delivers multiple billable or clinically actionable indications rather than blood pressure measurement alone. These are some of the key factors driving revenue growth of the market.

The WHO's second Global Hypertension Report found that only about one in five of the world's 1.4 billion hypertensive adults have their condition controlled. Monitoring access, not treatment availability, is the binding constraint.

The third driver is the early regulatory clearance of cuffless, photoplethysmography-based blood pressure technology in the United States and select international markets. Cuffless measurement works by extracting pulse wave features from an optical sensor rather than mechanically inflating a cuff, and because that approach eliminates the discomfort and inconvenience that limits adherence to cuff-based devices, regulatory clearance of a validated cuffless system directly addresses one of the category's primary adoption barriers. In July 2025, Aktiia received FDA 510(k) clearance for its Hilo Band, the first cuffless blood pressure monitor authorized for over-the-counter sale in the United States, and in September 2025, Sky Labs received approval from South Korea's Ministry of Food and Drug Safety for CART BP, a ring-type cuffless device enabling 24-hour continuous monitoring. The effect on the market is that the addressable population is widening from patients willing to use a cuff to anyone willing to wear a ring or wristband, provided regulatory clearance continues to expand. These are some of the key factors driving revenue growth of the market.

However, the blood pressure monitoring devices market faces severe adoption constraints from reimbursement gaps in low-income markets and unresolved accuracy questions for cuffless home monitoring.

Because home blood pressure monitoring devices are frequently an out-of-pocket purchase in markets without device-specific reimbursement policies, patients in lower-income healthcare systems continue to rely exclusively on office-based measurement despite guideline bodies including the American Heart Association and European Society of Hypertension increasingly recommending home monitoring for all diagnosed patients.

Cuffless accuracy validation compounds this, because photoplethysmography-based cuffless devices have not yet consistently demonstrated the ISO 81060-2 clinical-grade accuracy standard that cuff-based oscillometric systems meet, so most cuffless devices remain confined to a wellness rather than diagnostic-grade regulatory category even where select clearances exist.

Device literacy and technique variability is the third constraint, since accurate home blood pressure measurement depends on correct cuff sizing, positioning, and measurement technique, and inconsistent patient technique can produce misleading readings even with an accurately calibrated device, undermining the clinical value of guideline-recommended home monitoring.

These factors substantially limit blood pressure monitoring devices market growth over the forecast period.

Based on device type, the global blood pressure monitoring devices market is segmented into digital automatic BP monitors, mercury and aneroid sphygmomanometers, ambulatory blood pressure monitors, and wearable and cuffless BP devices. Digital automatic BP monitors hold the largest revenue share, because guideline-endorsed home monitoring is overwhelmingly conducted on oscillometric digital devices rather than manual sphygmomanometers, which suits a market where guideline compliance and ease of use drive purchasing more than any single feature. Mercury and aneroid sphygmomanometers remain established in clinical settings valuing manual auscultatory measurement and are cheaper per unit than any digital alternative, but they cannot deliver the AI-powered cardiac co-detection features increasingly built into digital platforms. Wearable and cuffless BP devices are expected to register the fastest revenue growth rate in the global blood pressure monitoring devices market over the forecast period, driven by Aktiia's and Sky Labs' 2025 regulatory clearances, which is why other cuffless developers are accelerating their own clinical validation programmes toward similar regulatory pathways.

Based on technology, the global blood pressure monitoring devices market is segmented into oscillometric technology, auscultatory technology, and photoplethysmography technology. Oscillometric technology holds the largest revenue share, because it remains the clinically validated basis for nearly all currently cleared digital and ambulatory BP monitors, which suits a market where regulatory precedent favours proven measurement technology over experimental approaches. Photoplethysmography technology is expected to register the fastest revenue growth rate in the global blood pressure monitoring devices market over the forecast period, driven by early cuffless regulatory clearances such as Aktiia's Hilo Band, which is why device makers are prioritising PPG-based sensing for their next-generation wearable platforms.

Based on end-use, the global blood pressure monitoring devices market is segmented into hospitals and clinics, home care settings, ambulatory care centres, and diagnostic laboratories. Home care settings hold the largest revenue share, because guideline bodies now recommend home monitoring as the default for diagnosed hypertensive patients rather than reserving it for select cases, which ties directly back to the guideline-driven demand described in the market's primary demand driver. Ambulatory care centres are expected to register the fastest revenue growth rate in the global blood pressure monitoring devices market over the forecast period, driven by CMS remote patient monitoring reimbursement codes that pay providers for reviewing patient-generated blood pressure data, which is why clinics are increasingly billing home monitoring data review as a remote monitoring service.

Based on regional analysis, the blood pressure monitoring devices market in North America accounted for largest revenue share in 2025. The United States leads because CMS remote patient monitoring reimbursement codes give providers a direct billing pathway for home-monitored blood pressure data, and because Omron Healthcare, Withings, Aktiia, and Apple all maintain their primary commercial and regulatory presence in the US market. Omron Corporation's Healthcare segment revenue anchors a domestic device infrastructure large enough to sustain multiple competing BP monitoring platforms simultaneously. The concentration of FDA clearance activity in the country also means new cardiac co-detection indications are typically launched in the United States first, before expanding to other regulatory jurisdictions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. The European Society of Hypertension's January 2026 consensus recommending home blood pressure monitoring for all diagnosed patients has driven longstanding clinical adoption across national health systems, and Schiller AG maintains a strong European institutional presence. The result is steady rather than rapid growth, shaped more by national health system procurement cycles than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan and South Korea represent two of the most advanced national markets within the region for BP monitoring technology. South Korea is the earlier-launch market for cuffless BP technology in the region, illustrated by Sky Labs' September 2025 MFDS approval for CART BP, which leaves more room for growth than in the already cuff-based-saturated North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private hospital and cardiology networks driving early adoption of AI-integrated BP monitors among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the precision pressure sensors and semiconductor components that Latin American device assemblers depend on, an effect expected to run through 2026 and slow blood pressure device adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding private hospital network and the UAE's regional distribution hubs represent the primary investment centres for blood pressure monitoring device adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the cardiology and specialist infrastructure needed to support advanced BP monitoring at scale.